The anaplastic lymphoma kinase (ALK) gene plays a crucial role in both normal brain development and oncogenesis, particularly in non-small cell lung cancer (NSCLC), anaplastic large cell lymphoma, and neuroblastoma [1]. In the context of metastatic ALK-positive NSCLC, where the ALK tyrosine kinase domain undergoes rearrangement, ALK tyrosine kinase inhibitors (TKIs) have emerged as a vital therapeutic strategy. These inhibitors target the abnormal ALK protein's ATP pocket, effectively impeding downstream phosphorylation and leading to tumor cell deactivation and death [2]. This evidence concerns the gene ALK and non-small cell lung carcinoma.